Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYS6010 + Osimertinib in EGFR+ NSCLC
NCT07256509Phase 2Not yet recruiting
- Sponsor
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Start
- Nov 2025
- Primary completion
- Nov 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
A Phase 2 trial of CPO301 in non-small cell lung cancer (NSCLC), sponsored by CSPC Megalith Biopharmaceutical Co., Ltd.. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
CPO301
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07256509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07256509.